U.S. flag An official website of the United States government
  1. Home
  2. Regulatory Information
  3. Search for FDA Guidance Documents
  4. CPG Sec. 160.600 Payment of Expert Witnesses
  1. Search for FDA Guidance Documents


CPG Sec. 160.600 Payment of Expert Witnesses October 1987

Issued by:
Guidance Issuing Office
Office of Regulatory Affairs


FDA Staff Manual Guide 2610.2 sets *limits for expert witness court appearance fees* in a Food and Drug case. The Department of Justice has no strict set limits and usually can pay considerably more than FDA in order to obtain expert witnesses.

Traditionally, FDA has paid expert fees in all of our cases. However, because of our fee limit, it has been difficult in some cases to obtain appropriate expert testimony. On occasion, in such cases, the local U.S. Attorney has paid all or part of those expert witness fees, particularly when that office has been particularly active in the case.

Department of Justice policy in payment of experts in Food and Drug cases has not always been clear or consistent and frequently depends on which part of the Department is involved, i.e., U.S. Attorney or Office of Consumer Litigation.


Accordingly, the agency should, in the first instance, assume that it will bear the cost of expert testimony to the limits of the FDA expert witness schedule. However, in the light of past history, whenever it seems appropriate or necessary to have a greater supply of funds for this purpose, the agency should inquire of the appropriate Department of Justice representative whether they will participate in the payment of such fees for the experts needed in our cases.

*Material between asterisks is new or revised*

Issued: 10/26/76

Revised: 11/29/77, 10/1/80, 12/3/86, 10/16/87

Submit Comments

Submit comments on this guidance document electronically via docket ID: FDA-2013-S-0610 - Specific Electronic Submissions Intended For FDA's Dockets Management Staff (i.e., Citizen Petitions, Draft Proposed Guidance Documents, Variances, and other administrative record submissions)

If unable to submit comments online, please mail written comments to:

Dockets Management
Food and Drug Administration
5630 Fishers Lane, Rm 1061
Rockville, MD 20852

All comments should be identified with the title of the guidance.

Back to Top